Boehringer Scores 2nd Bellwether Win In Conn. Pradaxa Suit

Law360 (May 7, 2018, 5:35 PM EDT) -- A Connecticut state jury on Monday sided with Boehringer Ingelheim Pharmaceuticals Inc. in a second bellwether trial as part of a consolidated state proceeding over the alleged bleeding risk of its blood thinner Pradaxa, rejecting a woman's claims that taking the drug landed her in the hospital.

A state jury in Hartford rejected Mary Lou Gallam's claims that taking Pradaxa caused her to be hospitalized in 2014 for two days for a gastrointestinal bleed. She had been taking the drug for 2½ years, and she claimed that neither she nor her doctors were adequately warned about the drug's risks and that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!